TACR1 and rhabdoid tumor: To probe the role of NK1R-SP-targeted therapies in rhabdoid tumors, we next investigated the effect of aprepitant on the RT tumor cell lines G-401, BT-12, and CHLA-266 with the human HB cell line HepG2 as a positive control and the primary dermal fibroblasts as a negative control for aprepitant response [19].